triiodothyronine has been researched along with Neuroectodermal Tumors, Primitive in 1 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Neuroectodermal Tumors, Primitive: A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059)
| Excerpt | Relevance | Reference |
|---|---|---|
| "From Jan 1998 to Feb 2001, a total of 37 euthyroid children scheduled for CSI for medulloblastoma/primitive neuroectodermal tumor underwent thyroid ultrasound and free triiodothyronine (FT3), free thyroxine (FT4), and TSH evaluation at the beginning and end of CSI." | 3.74 | Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. ( Biassoni, V; Bombardieri, E; Collini, P; Fossati-Bellani, F; Gandola, L; Marchianò, A; Massimino, M; Pallotti, F; Pignoli, E; Seregni, E; Serra, A; Spreafico, F; Terenziani, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Massimino, M | 1 |
| Gandola, L | 1 |
| Collini, P | 1 |
| Seregni, E | 1 |
| Marchianò, A | 1 |
| Serra, A | 1 |
| Pignoli, E | 1 |
| Spreafico, F | 1 |
| Pallotti, F | 1 |
| Terenziani, M | 1 |
| Biassoni, V | 1 |
| Bombardieri, E | 1 |
| Fossati-Bellani, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protection From Iatrogenic Hypothyroidism Patients With MBL and Pediatric Patients With HL and Non-HL Needing Radiotherapy on Thyroid Site[NCT05316922] | Phase 3 | 68 participants (Anticipated) | Interventional | 2021-12-13 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for triiodothyronine and Neuroectodermal Tumors, Primitive
| Article | Year |
|---|---|
Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor.
Topics: Adolescent; Adult; Biomarkers; Brain Neoplasms; Child; Child, Preschool; Cranial Irradiation; Diseas | 2007 |